Vincerx Pharma, Inc. Common Stock (VINC) - Total Assets
Based on the latest financial reports, Vincerx Pharma, Inc. Common Stock (VINC) holds total assets worth $4.69 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore VINC current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Vincerx Pharma, Inc. Common Stock - Total Assets Trend (2019–2024)
This chart illustrates how Vincerx Pharma, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Vincerx Pharma, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Vincerx Pharma, Inc. Common Stock's total assets of $4.69 Million consist of 80.1% current assets and 19.9% non-current assets. Also see VINC market cap overview for the company's overall valuation and market capitalisation.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 62.3% |
| Accounts Receivable | $1.04 Million | 13.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Vincerx Pharma, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Vincerx Pharma, Inc. Common Stock for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vincerx Pharma, Inc. Common Stock's current assets represent 80.1% of total assets in 2024, a decrease from 79104.1% in 2019.
- Cash Position: Cash and equivalents constituted 62.3% of total assets in 2024, down from 68470.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 13.0% of total assets.
Vincerx Pharma, Inc. Common Stock Competitors by Total Assets
Key competitors of Vincerx Pharma, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020
|
Germany | €22.06 Million |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.36 Billion |
Vincerx Pharma, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 0.72 | 9.87 |
| Quick Ratio | 1.79 | 0.72 | 9.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.07 Million | $-2.96 Million | $710.86K |
Vincerx Pharma, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Vincerx Pharma, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.03 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -56.1% |
| Total Assets | $8.01 Million |
| Market Capitalization | $66.48K USD |
Valuation Analysis
Below Book Valuation: The market values Vincerx Pharma, Inc. Common Stock's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vincerx Pharma, Inc. Common Stock's assets decreased by 56.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vincerx Pharma, Inc. Common Stock (2019–2024)
The table below shows the annual total assets of Vincerx Pharma, Inc. Common Stock from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.01 Million | -56.06% |
| 2023-12-31 | $18.22 Million | -69.27% |
| 2022-12-31 | $59.29 Million | -49.62% |
| 2021-12-31 | $117.68 Million | +86.22% |
| 2020-12-31 | $63.19 Million | +6319100.00% |
| 2019-12-31 | $1.00K | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more